These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 17136903)

  • 41. Value for money in drug treatment: economic evaluation of prison methadone.
    Warren E; Viney R; Shearer J; Shanahan M; Wodak A; Dolan K
    Drug Alcohol Depend; 2006 Sep; 84(2):160-6. PubMed ID: 16487668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV prevalence and related risk behaviours among prisoners in Iran: results of the national biobehavioural survey, 2009.
    Navadeh S; Mirzazadeh A; Gouya MM; Farnia M; Alasvand R; Haghdoost AA
    Sex Transm Infect; 2013 Nov; 89 Suppl 3(Suppl 3):iii33-6. PubMed ID: 23986417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia.
    Bick J; Culbert G; Al-Darraji HA; Koh C; Pillai V; Kamarulzaman A; Altice F
    Int J Prison Health; 2016 Dec; 12(4):253-269. PubMed ID: 27921633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV seroconversion among injection drug users in detention, Tehran, Iran.
    Jahani MR; Kheirandish P; Hosseini M; Shirzad H; Seyedalinaghi SA; Karami N; Valiollahi P; Mohraz M; McFarland W
    AIDS; 2009 Feb; 23(4):538-40. PubMed ID: 19182678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
    Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
    Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. International law, human rights and HIV/AIDS.
    Patterson D; London L
    Bull World Health Organ; 2002; 80(12):964-9. PubMed ID: 12571725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AIDS and prisons.
    Tomasevski K
    AIDS; 1991; 5 Suppl 2():S245-51. PubMed ID: 1845054
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatitis C in European prisons: a call for an evidence-informed response.
    Arain A; Robaeys G; Stöver H
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S17. PubMed ID: 25252822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prison health and public health responses at a regional prison in Western Australia.
    Gilles M; Swingler E; Craven C; Larson A
    Aust N Z J Public Health; 2008 Dec; 32(6):549-53. PubMed ID: 19076747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.
    Macalino GE; Vlahov D; Sanford-Colby S; Patel S; Sabin K; Salas C; Rich JD
    Am J Public Health; 2004 Jul; 94(7):1218-23. PubMed ID: 15226146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prevention and care of HIV-infected drug users in contemporary Brazil.
    Bastos FI
    Subst Use Misuse; 2006; 41(6-7):833-4. PubMed ID: 16809171
    [No Abstract]   [Full Text] [Related]  

  • 52. Alternatives to current HIV/AIDS policies and practices in South African prisons.
    Goyer KC; Gow J
    J Public Health Policy; 2002; 23(3):307-23. PubMed ID: 12325288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of harm reduction in prisons in seven European countries.
    Sander G; Scandurra A; Kamenska A; MacNamara C; Kalpaki C; Bessa CF; Laso GN; Parisi G; Varley L; Wolny M; Moudatsou M; Pontes NH; Mannix-McNamara P; Libianchi S; Antypas T
    Harm Reduct J; 2016 Oct; 13(1):28. PubMed ID: 27717368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Confronting HIV infection in prisons.
    Hankins C
    CMAJ; 1994 Sep; 151(6):743-5. PubMed ID: 7755688
    [No Abstract]   [Full Text] [Related]  

  • 55. Clean switch: the case for prison needle and syringe programs.
    Chu S
    HIV AIDS Policy Law Rev; 2009 Dec; 14(2):5-19. PubMed ID: 20225504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV, prisoners, and human rights.
    Rubenstein LS; Amon JJ; McLemore M; Eba P; Dolan K; Lines R; Beyrer C
    Lancet; 2016 Sep; 388(10050):1202-14. PubMed ID: 27427457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program.
    Bachireddy C; Shrestha R; Bromberg DJ; Azbel L; Kurmanalieva A; Wegman M; Shumskaya N; Rozanova J; Meyer JP; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103558. PubMed ID: 34915426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
    Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
    Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Towards equivalent health care of prisoners: European soft law and public health policy in Geneva.
    Elger BS
    J Public Health Policy; 2008 Jul; 29(2):192-206. PubMed ID: 18523474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.